Trajectories of recovery in depressed Parkinson's disease patients treated with paroxetine or venlafaxine.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Parkinsonism & Related Disorders

• Publication date

  2016-02-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1016/j.parkreldis.2015.12.013PMID 26739248
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cognitive dysfunction in major depressive disorder: a state-of-the-art clinical review.

  2015cited by this paper
• Factor analysis of the Hamilton Depression Rating Scale in Parkinson's disease.

  2015cited by this paper
• Antiparkinson drug use and adherence in medicare part D beneficiaries with Parkinson's disease.

  2013cited by this paper
• A Meta-Analysis of Randomised Placebo-Controlled Treatment Trials for Depression and Anxiety in Parkinson’s Disease

  2013cited by this paper
• Systematic review on factors associated with medication non-adherence in Parkinson's disease.

  2012cited by this paper
• Treatment of Comorbid Anxiety and Depression with Escitalopram: Results of a Post-Marketing Surveillance Study

  2012cited by this paper
• A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease

  2012cited by this paper
• Trajectories of depression severity in clinical trials of duloxetine: insights into antidepressant and placebo responses.

  2011cited by this paper
• Prevalence and cost of medication nonadherence in Parkinson's disease: Evidence from administrative claims data

  2010cited by this paper
• Efficacy and acceptability of selective serotonin reuptake inhibitors for the treatment of depression in Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials

  2010cited by this paper
• Trajectories of change in depression severity during treatment with antidepressants

  2009cited by this paper
• Medication adherence and associated outcomes in medicare health maintenance organization‐enrolled older adults with Parkinson's disease

  2008cited by this paper
• A systematic review of prevalence studies of depression in Parkinson's disease

  2008cited by this paper
• Depression in Parkinson’s disease: Health risks, etiology, and treatment options

  2008cited by this paper
• Anxiety and depression: main determinants of health-related quality of life in Brazilian patients with Parkinson's disease.

  2008cited by this paper
• Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: A double‐blind, randomized, placebo‐controlled study

  2008cited by this paper
• Sydney multicenter study of Parkinson's disease: Non‐L‐dopa–responsive problems dominate at 15 years

  2005cited by this paper
• A systematic review of prevalence studies of dementia in Parkinson's disease

  2005cited by this paper
• Tolerability and adherence issues in antidepressant therapy.

  2003cited by this paper
• Discontinuing or Switching Selective Serotonin-Reuptake Inhibitors

  2002cited by this paper
• Depression in idiopathic Parkinson's disease treated with citalopram: A placebo-controlled trial

  1998cited by this paper
• A population perspective on diagnostic criteria for Parkinson's disease

  1997cited by this paper
• Course of psychomotor agitation during pharmacotherapy of depression: Analysis from double‐blind controlled trials with fluoxetine

  1996cited by this paper
• Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients.

  1996cited by this paper
• A New Depression Scale Designed to be Sensitive to Change

  1979cited by this paper
• “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician

  1975cited by this paper
• A RATING SCALE FOR DEPRESSION

  1960cited by this paper

• Noradrenergic therapies in neurodegenerative disease: from symptomatic to disease modifying therapy?

  2025cites this paper
• The effects of paroxetine therapy on depressive symptom and motor function in the treatment of depression with Parkinson’s disease: A meta-analysis

  2023cites this paper
• Comparative efficacy and acceptability of drug treatments for Parkinson's disease with depression: A systematic review with network meta-analysis.

  2022cites this paper
• Depression After Parkinson’s Disease: Treated Differently or Not At All?

  2022cites this paper
• Antidepressants Effects on Pain in Parkinson Disease: A Systematic Review

  2021cites this paper
• Correlation between depression and quality of life in patients with Parkinson's disease.

  2021cites this paper
• Toward heterogeneous information fusion: bipartite graph convolutional networks for in silico drug repurposing

  2020cites this paper
• Neuropsychiatric aspects of Parkinson disease psychopharmacology: Insights from circuit dynamics.

  2019cites this paper
• A simple, efficient and rapid HPLC–UV method for the detection of 5-HT in RIN-14B cell extract and cell culture medium

  2019cites this paper
• The involvement of the pathway connecting the substantia nigra, the periaqueductal gray matter and the retrotrapezoid nucleus in breathing control in a rat model of Parkinson's disease

  2018cites this paper
• СONDITIONS AND FACTORS OF FORMATION OF A PROLONGED COURSE OF NEUROTIC DEPRESSIONS

  2018cites this paper
• Drug Repositioning to Accelerate Drug Development Using Social Media Data: Computational Study on Parkinson Disease

  2018cites this paper
• Impairment of Serotonergic Transmission by the Antiparkinsonian Drug L-DOPA: Mechanisms and Clinical Implications

  2017cites this paper
• Antiparkinsonian Treatment for Depression in Parkinson's Disease: Are Selective Serotonin Reuptake Inhibitors Recommended?

  2016cites this paper
• New Pharmacological Approaches to Treating Non-Motor Symptoms of Parkinson’s Disease

  2016cites this paper